The Australian medical landscape is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 medication showing impressive results in early trials for addressing obesity. This therapy suggests https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/